![CNS relapse. (A) The 12-month cumulative risk of CNS relapse after CNS-BRT and CART was 25.0% (95% CI, 6-52). (B) Images showing the CNS-BRT treatment plans to the 50% isodose line. Patient 1: sagittal postcontrast computed tomography (CT) of the head with RT field targeting the orbits. Patient 3: sagittal noncontrast CT of the spine with RT field targeting T11 through L3. Patient 12: axial noncontrast CT of the head with RT field targeting the right gangliocapsular area. (C) Images show sites of post-CART CNS relapse. Patient 1: sagittal positron emission tomography (PET)/CT showing [¹⁸F]fluorodeoxyglucose (FDG)-avid relapse in the brain, 1 month after CAR T-cell infusion (white arrow). Patient 3: sagittal PET/CT showing 2 FDG-avid sites of relapse at the margins of prior RT field, 1 month after CAR T-cell infusion (white arrows). Patient 12: axial postcontrast T1 MRI showing a left periventricular relapse, 5 months after CAR T-cell infusion (white arrows).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/8/19/10.1182_bloodadvances.2024013393/1/blooda_adv-2024-013393-gr3.jpeg?Expires=1732490546&Signature=FRTvKGebmqjHp3lgQ288TH9FQtUarbckFmMsBhENvmriiozIIqTgLEMuasxkCUu0NqUgpN5KsH~QijfWe-9tnaAIst~rrgxWisOUqRM6vHtKOAh2eCh3RWCM-r3KSXhCR2VZ1zK3LTTpRPWRP-K9moUwo6TgGNemeLhbD9uciD7Smp3C2xKKX6R4UHTWcr6mJAGUj3uKaGxZ1fnejBfPuZkaVCtuKtF6nAJlPjKwCVpw4c0BtVgvZlVmYnCqNQTpCSfwC-z4lxajCaWJmyMoqRzfAQhaVggawXpZdt5MNO~sV7eLfenecW4hDr4RgnNnWgQ3lx9F2ygIB8PJt4FvtA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CNS relapse. (A) The 12-month cumulative risk of CNS relapse after CNS-BRT and CART was 25.0% (95% CI, 6-52). (B) Images showing the CNS-BRT treatment plans to the 50% isodose line. Patient 1: sagittal postcontrast computed tomography (CT) of the head with RT field targeting the orbits. Patient 3: sagittal noncontrast CT of the spine with RT field targeting T11 through L3. Patient 12: axial noncontrast CT of the head with RT field targeting the right gangliocapsular area. (C) Images show sites of post-CART CNS relapse. Patient 1: sagittal positron emission tomography (PET)/CT showing [¹⁸F]fluorodeoxyglucose (FDG)-avid relapse in the brain, 1 month after CAR T-cell infusion (white arrow). Patient 3: sagittal PET/CT showing 2 FDG-avid sites of relapse at the margins of prior RT field, 1 month after CAR T-cell infusion (white arrows). Patient 12: axial postcontrast T1 MRI showing a left periventricular relapse, 5 months after CAR T-cell infusion (white arrows).
